Xilio Therapeutics, Inc. (XLO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 8,084 | 2,930 | 2,263 | 2,357 |
| Restructuring charges | - | - | -41 | 30 |
| Research and development | 15,330 | 8,266 | 10,759 | 11,216 |
| General and administrative | 7,120 | 8,515 | 6,307 | 5,815 |
| Total operating expenses | 22,450 | 16,781 | 17,025 | 17,061 |
| Loss from operations | -14,366 | -13,851 | -14,762 | -14,704 |
| Other income, net | -1,428 | 586 | 742 | 779 |
| Change in fair value of common stock warrant liabilities | 50 | - | - | - |
| Total other income (expense), net | -1,478 | 586 | 742 | 779 |
| Net loss | - | -13,265 | -14,020 | -13,925 |
| Net loss and comprehensive loss | -15,844 | -13,265 | -14,020 | -13,925 |
| Earnings per share, basic | -0.16 | -0.18 | -0.22 | -0.24 |
| Earnings per share, diluted | -0.16 | -0.18 | -0.22 | -0.24 |
| Weighted average number of shares outstanding, basic | 96,447,672 | 74,700,364 | 63,465,063 | 57,760,178 |